ICL spinout Cagen raised an undisclosed sum from Imperial Innovations and UKI2S to commercialise protein nanocages for shielding therapeutic payloads.
Cagen, a UK-based synthetic biology spinout of Imperial College of London, made its public debut yesterday with a seed round of undisclosed size backed by the university’s tech transfer affiliate, Imperial Innovations
The round also featured UK Innovation & Science Seed Fund, a $30m government-backed VC fund focused on building technologies from publicly-funded research centres.
Cagen’s self-assembling protein nanocages have been designed to shield therapeutic payloads from degradation or excess toxicity while travelling through the body.
Better modulation of certain…